PLUS Diagnostics First National Laboratory to Offer Highly Specialized Gastrointestinal...

PLUS Diagnostics First National Laboratory to Offer Highly Specialized
Gastrointestinal Tests

Company Expands Diagnostic Services with K9 Clone DOG-1 Immunohistochemical
and H. pylori Monoclonal Antibody Tests

LAKEWOOD, N.J., June 1 /PRNewswire/ -- PLUS Diagnostics, a leading U.S.
anatomic pathology company offering a full range of multi-specialty services,
announced today that it is the first national laboratory to offer a highly
specialized test that definitively diagnoses the rare gastrointestinal stromal
tumor ("GIST"). Known as the K9 clone DOG-1 immunohistochemical assay, the
new test is expected to identify up to 15 percent more people who suffer from
the tumor than current tests.

PLUS Diagnostics also announced that it is the first U.S. laboratory to beta
test an H. pylori monoclonal antibody test that detects H. pylori infection.
Afflicting as many as 30 percent of Americans, H. pylori can be difficult to
distinguish from other bacteria in routine staining assays. The infection,
which is commonly caused by ingesting contaminated water or food, can cause
peptic ulcer disease and gastric malignancy when left untreated. PLUS
Diagnostics' new test is expected to reduce the number of false positive H.
pylori cases.

"These tests are at the forefront of science and innovation, and support our
goal of providing our customers with leading diagnostic services that enable
them to offer their patients the highest quality of care," said Doug Berg,
chief executive officer, PLUS Diagnostics. "We will continue to identify and
invest in the newest tests and technologies that are uniquely tailored to
supporting doctors and specialists with diagnosing a range of cancers and
disorders."

Dr. Ali Riba, associate medical director for PLUS Diagnostics, added: "It is
exciting to be part of a laboratory that is significantly investing in
gastrointestinal services. We have the potential to help doctors save lives
by definitively diagnosing the rare GIST tumor when traditional tests are not
able to do so. Similarly, our beta test for H. pylori is expected to improve
the accuracy of today's immunohistochemical tests, so doctors can immediately
determine whether their patients require treatment."

PLUS Diagnostics has expanded its services since the company partnered with
Water Street Healthcare Partners, a leading private equity firm focused
exclusively on health care. It recently opened a West Coast laboratory and
announced plans to expand into diagnostics services for hematology/oncology,
in addition to the gastroenterology and urology specialties it serves today.

About PLUS Diagnostics
PLUS Diagnostics is a leading national anatomic pathology company that
provides a full range of multi-specialty services, including extensive
diagnostic procedures and specialist consultations. Accredited by the College
of American Pathologists, PLUS Diagnostics has long been recognized for
exceptional service and quality. The company currently focuses on a broad base
of specialty pathology services, including urology and gastroenterology with
plans to expand into hematopathology this year. For more information, visit,
www.plusdx.com.

SOURCE PLUS Diagnostics

Marv Kogan, +1-847-948-0099, marv@mediadirections.net, for PLUS Diagnostics;
or Kelly Zitlow of Water Street Healthcare Partners, +1-847-858-5230,
kelly.zitlow@wshp.com